What is Ikonisys?
Ikonisys SA operates as a specialized diagnostics entity with a multinational footprint spanning France, the United States, and Italy. The company is primarily engaged in the development, production, and commercialization of the Ikoniscope20 platform, a sophisticated, fully-automated system engineered for the detection and analysis of rare cells. Its market position is bolstered by FDA clearances and CE certifications, which facilitate the deployment of its diagnostic applications in both North American and European healthcare sectors. Beyond its core microscopy offerings, Ikonisys is actively expanding its portfolio to include advanced liquid biopsy tests, specifically targeting Circulating Tumor Cells (CTC) to improve early-stage cancer detection outcomes.
How much funding has Ikonisys raised?
Ikonisys has raised a total of $56.4M across 10 funding rounds:
Unspecified
$3.8M
Unspecified
$1.4M
Debt
$117K
Debt
$6.3M
Share Placement
$535K
Share Placement
$208K
Other Financing Round
$541K
Unspecified (2010): $3.8M featuring Trevi Health Ventures and Goldman Sachs
Unspecified (2012): $1.4M backed by Trevi Health Ventures and Syneresis s.r.l.
Debt (2021): $117K with participation from PPP
Debt (2022): $6.3M led by Negma Group
Share Placement (2023): $535K supported by The Cambria Group
Share Placement (2024): $208K, investors not publicly disclosed
Other Financing Round (2025): $541K, investors not publicly disclosed
Key Investors in Ikonisys
Trevi Health Ventures
A specialist investment firm providing healthcare-focused alternative asset management, with a deep emphasis on medical devices and biopharmaceuticals.
Goldman Sachs
A leading global investment banking and securities firm that provides strategic advisory and capital market services to institutional clients.
Lakeview Capital Management
An independent, boutique investment advisory firm focused on wealth management and strategic capital allocation for high-net-worth entities.
What's next for Ikonisys?
The recent infusion of capital positions Ikonisys to accelerate its research and development pipeline, particularly regarding the commercialization of its liquid biopsy diagnostic suite. As the company transitions through this latest phase of growth, the strategic focus will likely remain on expanding the clinical utility of the Ikoniscope20 platform. By optimizing its automated workflows, Ikonisys aims to address critical unmet needs in oncology, potentially increasing its market share in the competitive landscape of precision medicine. Future milestones will likely involve further regulatory submissions and the scaling of its commercial infrastructure to support broader adoption of its proprietary fluorescence microscopy technology.
See full Ikonisys company page
